AAPL327.46+2.50 (+0.77%) ▲|ABBV260.94-0.78 (-0.30%) ▼|ABT108.42-2.05 (-1.86%) ▼|ACN193.77+6.09 (+3.24%) ▲|ADBE285.34+5.55 (+1.98%) ▲|AMAT435.64-2.82 (-0.64%) ▼|AMD456.72-0.34 (-0.07%) ▼|AMGN442.96+0.12 (+0.03%) ▲|AMT178.11+5.19 (+3.00%) ▲|AMZN258.46+3.48 (+1.36%) ▲|AVGO358.20-9.04 (-2.46%) ▼|AXP330.43+0.45 (+0.14%) ▲|BA210.45+1.58 (+0.76%) ▲|BAC63.15+0.55 (+0.88%) ▲|BKNG195.95-3.65 (-1.83%) ▼|BLK1,121.69+14.61 (+1.32%) ▲|BMY67.68+0.02 (+0.02%) ▲|BNY164.06+2.02 (+1.25%) ▲|BRK-B507.69+2.45 (+0.48%) ▲|C138.22+3.88 (+2.88%) ▲|CAT794.72+2.44 (+0.31%) ▲|CL89.94-0.16 (-0.18%) ▼|CMCSA26.65-0.17 (-0.62%) ▼|COF220.72+4.12 (+1.90%) ▲|COP135.89-1.31 (-0.95%) ▼|COST928.12-0.36 (-0.04%) ▼|CRM265.47+8.54 (+3.32%) ▲|CSCO108.83-0.63 (-0.57%) ▼|CVS96.89-0.34 (-0.35%) ▼|CVX211.82+0.04 (+0.02%) ▲|DE686.59-11.78 (-1.69%) ▼|DHR210.43+0.52 (+0.25%) ▲|DIS107.35-0.63 (-0.58%) ▼|DUK121.50+0.94 (+0.78%) ▲|EMR150.08+1.10 (+0.74%) ▲|FDX322.88+6.34 (+2.00%) ▲|GD364.10+0.03 (+0.01%) ▲|GE332.68+3.18 (+0.96%) ▲|GEV940.50+18.56 (+2.01%) ▲|GILD150.83+1.22 (+0.82%) ▲|GM87.02+2.15 (+2.53%) ▲|GOOG339.67+5.89 (+1.76%) ▲|GOOGL343.02+5.90 (+1.75%) ▲|GS1,035.87+31.45 (+3.13%) ▲|HD318.02+1.84 (+0.58%) ▲|HON207.47+1.40 (+0.68%) ▲|IBM233.06+1.36 (+0.59%) ▲|INTC91.07+1.02 (+1.13%) ▲|INTU346.71+3.77 (+1.10%) ▲|ISRG370.58-1.31 (-0.35%) ▼|JNJ278.18+2.97 (+1.08%) ▲|JPM362.35+6.13 (+1.72%) ▲|KO89.11+0.87 (+0.98%) ▲|LIN482.68-3.18 (-0.65%) ▼|LLY1,155.47-4.61 (-0.40%) ▼|LMT531.36-0.19 (-0.04%) ▼|LOW202.71+2.87 (+1.44%) ▲|LRCX290.89+2.57 (+0.89%) ▲|MA584.95-3.19 (-0.54%) ▼|MCD259.62-1.33 (-0.51%) ▼|MDLZ61.39-1.07 (-1.71%) ▼|MDT92.46+0.28 (+0.30%) ▲|META613.49+20.64 (+3.48%) ▲|MMM168.13-0.63 (-0.37%) ▼|MO69.78+0.22 (+0.31%) ▲|MRK151.65+0.01 (+0.01%) ▲|MS217.00+5.18 (+2.44%) ▲|MSFT511.22+14.40 (+2.90%) ▲|MU947.50-8.58 (-0.90%) ▼|NEE84.09+0.99 (+1.19%) ▲|NFLX82.69-0.05 (-0.05%) ▼|NKE38.76+0.52 (+1.36%) ▲|NOW145.75+9.03 (+6.60%) ▲|NVDA229.46+5.05 (+2.25%) ▲|ORCL155.64+9.89 (+6.78%) ▲|PEP140.32-0.20 (-0.14%) ▼|PFE28.72-0.30 (-1.03%) ▼|PG147.30-0.34 (-0.23%) ▼|PLTR183.78+14.32 (+8.45%) ▲|PM187.37-0.57 (-0.30%) ▼|QCOM169.38+0.34 (+0.20%) ▲|RTX201.69+0.91 (+0.45%) ▲|SBUX106.01-0.72 (-0.67%) ▼|SCHW110.64+2.40 (+2.22%) ▲|SO88.97+0.66 (+0.74%) ▲|SPG211.46+1.26 (+0.60%) ▲|T26.16+0.21 (+0.79%) ▲|TMO616.47+7.93 (+1.30%) ▲|TMUS188.54+1.24 (+0.66%) ▲|TSLA380.80+23.79 (+6.66%) ▲|TXN252.80-2.00 (-0.78%) ▼|UBER75.85-0.60 (-0.78%) ▼|UNH400.39+0.73 (+0.18%) ▲|UNP290.09+0.36 (+0.12%) ▲|UPS103.38+0.37 (+0.36%) ▲|USB63.57+0.80 (+1.27%) ▲|V378.60+0.20 (+0.05%) ▲|VZ50.65+0.43 (+0.85%) ▲|WFC89.15-0.13 (-0.14%) ▼|WMT108.75+2.66 (+2.51%) ▲|XOM162.76-1.39 (-0.85%) ▼|AAPL327.46+2.50 (+0.77%) ▲|ABBV260.94-0.78 (-0.30%) ▼|ABT108.42-2.05 (-1.86%) ▼|ACN193.77+6.09 (+3.24%) ▲|ADBE285.34+5.55 (+1.98%) ▲|AMAT435.64-2.82 (-0.64%) ▼|AMD456.72-0.34 (-0.07%) ▼|AMGN442.96+0.12 (+0.03%) ▲|AMT178.11+5.19 (+3.00%) ▲|AMZN258.46+3.48 (+1.36%) ▲|AVGO358.20-9.04 (-2.46%) ▼|AXP330.43+0.45 (+0.14%) ▲|BA210.45+1.58 (+0.76%) ▲|BAC63.15+0.55 (+0.88%) ▲|BKNG195.95-3.65 (-1.83%) ▼|BLK1,121.69+14.61 (+1.32%) ▲|BMY67.68+0.02 (+0.02%) ▲|BNY164.06+2.02 (+1.25%) ▲|BRK-B507.69+2.45 (+0.48%) ▲|C138.22+3.88 (+2.88%) ▲|CAT794.72+2.44 (+0.31%) ▲|CL89.94-0.16 (-0.18%) ▼|CMCSA26.65-0.17 (-0.62%) ▼|COF220.72+4.12 (+1.90%) ▲|COP135.89-1.31 (-0.95%) ▼|COST928.12-0.36 (-0.04%) ▼|CRM265.47+8.54 (+3.32%) ▲|CSCO108.83-0.63 (-0.57%) ▼|CVS96.89-0.34 (-0.35%) ▼|CVX211.82+0.04 (+0.02%) ▲|DE686.59-11.78 (-1.69%) ▼|DHR210.43+0.52 (+0.25%) ▲|DIS107.35-0.63 (-0.58%) ▼|DUK121.50+0.94 (+0.78%) ▲|EMR150.08+1.10 (+0.74%) ▲|FDX322.88+6.34 (+2.00%) ▲|GD364.10+0.03 (+0.01%) ▲|GE332.68+3.18 (+0.96%) ▲|GEV940.50+18.56 (+2.01%) ▲|GILD150.83+1.22 (+0.82%) ▲|GM87.02+2.15 (+2.53%) ▲|GOOG339.67+5.89 (+1.76%) ▲|GOOGL343.02+5.90 (+1.75%) ▲|GS1,035.87+31.45 (+3.13%) ▲|HD318.02+1.84 (+0.58%) ▲|HON207.47+1.40 (+0.68%) ▲|IBM233.06+1.36 (+0.59%) ▲|INTC91.07+1.02 (+1.13%) ▲|INTU346.71+3.77 (+1.10%) ▲|ISRG370.58-1.31 (-0.35%) ▼|JNJ278.18+2.97 (+1.08%) ▲|JPM362.35+6.13 (+1.72%) ▲|KO89.11+0.87 (+0.98%) ▲|LIN482.68-3.18 (-0.65%) ▼|LLY1,155.47-4.61 (-0.40%) ▼|LMT531.36-0.19 (-0.04%) ▼|LOW202.71+2.87 (+1.44%) ▲|LRCX290.89+2.57 (+0.89%) ▲|MA584.95-3.19 (-0.54%) ▼|MCD259.62-1.33 (-0.51%) ▼|MDLZ61.39-1.07 (-1.71%) ▼|MDT92.46+0.28 (+0.30%) ▲|META613.49+20.64 (+3.48%) ▲|MMM168.13-0.63 (-0.37%) ▼|MO69.78+0.22 (+0.31%) ▲|MRK151.65+0.01 (+0.01%) ▲|MS217.00+5.18 (+2.44%) ▲|MSFT511.22+14.40 (+2.90%) ▲|MU947.50-8.58 (-0.90%) ▼|NEE84.09+0.99 (+1.19%) ▲|NFLX82.69-0.05 (-0.05%) ▼|NKE38.76+0.52 (+1.36%) ▲|NOW145.75+9.03 (+6.60%) ▲|NVDA229.46+5.05 (+2.25%) ▲|ORCL155.64+9.89 (+6.78%) ▲|PEP140.32-0.20 (-0.14%) ▼|PFE28.72-0.30 (-1.03%) ▼|PG147.30-0.34 (-0.23%) ▼|PLTR183.78+14.32 (+8.45%) ▲|PM187.37-0.57 (-0.30%) ▼|QCOM169.38+0.34 (+0.20%) ▲|RTX201.69+0.91 (+0.45%) ▲|SBUX106.01-0.72 (-0.67%) ▼|SCHW110.64+2.40 (+2.22%) ▲|SO88.97+0.66 (+0.74%) ▲|SPG211.46+1.26 (+0.60%) ▲|T26.16+0.21 (+0.79%) ▲|TMO616.47+7.93 (+1.30%) ▲|TMUS188.54+1.24 (+0.66%) ▲|TSLA380.80+23.79 (+6.66%) ▲|TXN252.80-2.00 (-0.78%) ▼|UBER75.85-0.60 (-0.78%) ▼|UNH400.39+0.73 (+0.18%) ▲|UNP290.09+0.36 (+0.12%) ▲|UPS103.38+0.37 (+0.36%) ▲|USB63.57+0.80 (+1.27%) ▲|V378.60+0.20 (+0.05%) ▲|VZ50.65+0.43 (+0.85%) ▲|WFC89.15-0.13 (-0.14%) ▼|WMT108.75+2.66 (+2.51%) ▲|XOM162.76-1.39 (-0.85%) ▼|
29.8 C
New York
Thursday, September 3, 2026

Tag: cancer

TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient

First patient in Cohort B achieved CR after 2nd dose of TCB008EDINBURGH, Scotland, June 11, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC (NASDAQ: TCBP), a...

Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

Premier Research to support submission of an Expanded Access Program (EAP) application. This move positions Hoth to offer compassionate access to HT-001 for cancer patients...

Ping An Good Doctor Revamps Brand and Launches Annual Healthcare Service Brand

HONG KONG and SHANGHAI, June 11, 2025 /PRNewswire/ -- The Ping An Good Doctor Brand Revamp & Ping An Healthcare Services Brand Launch Conference was...

Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

Pasithea adds ETS2 expert Dr. James Lee to its SAB to guide PAS-004 development for IBD and other inflammatory diseases driven by ETS2.

Simtra BioPharma Solutions and MilliporeSigma Announce Strategic Alliance for Antibody Drug Conjugates Drug Substance and Drug Product Manufacturing Services

Proven leaders in biologics manufacturing are aligning their strengths to deliver a more efficient and cost-optimized drug development supply chain, worldwide Alliance aims to expedite...

Teleflex Highlights Prostate Health and Quality-of-Life Awareness Through Two Key Public Initiatives During Men’s Health Month

Timed with National Men’s Health Month, the Prostate Monster ad campaign shines a light on quality-of-life issues associated with benign prostatic hyperplasia or BPH—a condition affecting millions of men1—and encourages them to take control of their health.

Messenger RNA Market Research Report 2025-2035, Competitive Analysis of Pfizer, GSK, Arcturus Therapeutics, AstraZeneca, Beam Therapeutics, Moderna, Oncotelic, SK Bioscience, Sangamo, Sanofi CureVac

mRNA Market Surges: The global mRNA market is booming, fueled by the success of COVID-19 vaccines, with applications expanding to cancer and genetic disorders. Driven by public-private investments, the industry sees pharmaceutical giants like Pfizer and Moderna spearheading innovations. Despite challenges such as high costs, the market is set for substantial growth through 2035, with North America leading due to its robust healthcare infrastructure. Recent collaborations, such as Etherna Immunotherapies with Dropshot Therapeutics, are further accelerating RNA therapeutic developments.
mRNA Market Surges: The global mRNA market is booming, fueled by the success of COVID-19 vaccines, with applications expanding to cancer and genetic disorders. Driven by public-private investments, the industry sees pharmaceutical giants like Pfizer and Moderna spearheading innovations. Despite challenges such as high costs, the market is set for substantial growth through 2035, with North America leading due to its robust healthcare infrastructure. Recent collaborations, such as Etherna Immunotherapies with Dropshot Therapeutics, are further accelerating RNA therapeutic developments.

Kanazawa University research: High-speed AFM and 3D modelling help towards understanding the dynamics of a protein implicated in several cancers

KANAZAWA, Japan, June 11, 2025 /PRNewswire/ -- Researchers at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University observe and model how the enzyme ADAR1 interacts...

Fosun International Receives the “ESG & Sustainability Award” and Two Other Prestigious Honors from Global Banking and Finance Review

HONG KONG, June 11, 2025 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656) was recently notified by the renowned British finance magazine, Global...

Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer

CHENGDU, China, June 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT)...

Quest PharmaTech Announces Opposition to OQPBIOM’s Acquisition of AdBioTech

EDMONTON, Alberta, June 10, 2025 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, announced today that Quest was not informed or consulted, opposes and will not support the recently announced acquisition by privately held South Korea-based OQPBIOM Inc. (“OQM”) of a controlling interest in AdBioTech Co., Ltd. (“AdBioTech”), a public company listed on KOSDAQ in South Korea. OQM has announced that AdBioTech is the corporate vehicle through which it wishes to pursue the funding and advancement of its immunotherapy assets.

Porsche Experience Centre Toronto 911 GT3 RS being auctioned for charity through RM Sotheby’s

TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Porsche Cars Canada, Ltd. (PCL), importer and distributor for the sports car manufacturer from Stuttgart, announced that ahead of the opening of its Porsche Experience Centre (PEC) Toronto on June 18, a special 911 GT3 RS is being auctioned off through RM Sotheby’s.

Mise aux enchères de la 911 GT3 RS du Centre d’expérience Porsche de Toronto par l’entremise de RM Sotheby’s pour récolter des fonds pour...

TORONTO, 10 juin 2025 (GLOBE NEWSWIRE) -- Automobiles Porsche Canada, Ltée (PCL), l’importateur et le distributeur du constructeur de voitures de sport de Stuttgart, a annoncé qu’avant l’ouverture de son Centre d’expérience Porsche de Toronto le 18 juin, une 911 GT3 RS spéciale sera vendue aux enchères par l’entremise de RM Sotheby’s.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCancer